Novo NordiskSee all their emails

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

A real announcement email from Novo Nordisk. Captured May 22, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1) email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk announces a positive CHMP opinion for Wegovy 7.2 mg in a single-dose pen, with an expected EU launch in Q3 2026.

A standard corporate press release layout. The logo is at the top, followed by a bulleted summary, detailed body text, a data table, and contact information. The structure is strictly text-based with minimal whitespace.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.